Application No.: 08/402,394 Attorney Docket No. 02481.0790-02

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

- 1.-20. (Canceled)
- 21. (Previously Presented) A method for the preparation of a mono-Arg-insulin compound of formula II

in which A(1-21) and B(1-30) denote the A and B chains of human insulin and the -S-S-bridges are positioned as in insulin, which comprises:

(a) expressing in a bacterium a DNA molecule encoding a fusion protein which comprises a mini-proinsulin compound of the formula:

- (b) liberating said mini-proinsulin compound from said fusion protein;
- (c) folding and forming disulfide bridges in said mini-proinsulin compound;
- (d) incubating said mini-proinsulin compound with trypsin; and
- (e) precipitating the mono-Arg-insulin.

FINNEGAN HENDERSON FARABOW GARRETT & DUNNER LLP

- 22. (Previously Presented) A method for the preparation of insulin which comprises:
- (a) expressing in a bacterium a DNA molecule encoding a fusion protein which comprises a mini-proinsulin compound of the formula:

in which B(1-30) and A(1-21) denote the B and A chains of insulin;

- (b) liberating said mini-proinsulin compound from said fusion protein;
- (c) folding and forming disulfide bridges in said mini-proinsulin compound;
- (d) simultaneously incubating said mini-proinsulin compound with trypsin and carboxypeptidase B; and
 - (e) precipitating the insulin.
- 23. (Previously Presented) A method as claimed in claim 22, wherein step (d) is carried out in one vessel without having to isolate as an intermediate mono-Arg-insulin of formula II

FINNEGAN HENDERSON FARABOW GARRETT & DUNNER LLP

Attorney Docket No. 02481.0790-02

Application No.: 08/402,394

24. (Canceled)

25. (Previously Presented) A method for the preparation of a mono-Arg-insulin compound of formula II

in which A(1-21) and B(1-30) denote the A and B chains of human insulin and the -S-S-bridges are positioned as in insulin, which comprises:

(a) expressing in a bacterium a DNA molecule encoding a fusion protein which comprises

bonded via a bridging member,

to a peptide which stabilizes the fusion protein;

- (b) liberating a mini-proinsulin compound from said fusion protein by cleaving the expressed fusion protein resulting from step (a) with cyanogen bromide;
 - (c) folding and forming disulfide bridges in said mini-proinsulin compound;
 - (d) incubating said mini-proinsulin compound with trypsin; and
 - (e) precipitating the mono-Arg-insulin.

FINNEGAN HENDERSON FARABOW GARRETT & DUNNER LLP

- 26. (Previously Presented) A method for the preparation of insulin which comprises:
- (a) expressing in a bacterium a DNA molecule encoding a fusion protein which comprises

bonded via a bridging member,

to a peptide which stabilizes the fusion protein;

- (b) liberating a mini-proinsulin compound from said fusion protein by cleaving the expressed fusion protein resulting from step (a) with cyanogen bromide;
 - (c) folding and forming disulfide bridges in said mini-proinsulin compound;
- (d) simultaneously incubating said mini-proinsulin compound with trypsin and carboxypeptidase B; and
 - (e) precipitating the insulin.
- 27. (Previously Presented) A method as claimed in claim 26, wherein step (d) is carried out in one vessel without having to isolate as an intermediate mono-Arg-insulin of the formula II

FINNEGAN HENDERSON FARABOW GARRETT & DUNNER LLP

Application No.: 08/402,394

Attorney Docket No. 02481.0790-02

28-38. (Canceled)

39. (Previously Presented) A method for the preparation of a compound of the formula II

wherein A(1-21) and B(1-30) denote the A and B chains of human insulin and the -S-S-bridges are positioned as in insulin, comprising:

(a) expressing a DNA sequence encoding the compound of formula I

in a bacterium; and

- (b) cleaving the expressed compound of step (a) with trypsin.
- 40. (Previously Presented) A method for the preparation of insulin comprising:
 - (a) expressing a DNA sequence encoding the compound of formula I

$$B(1-30)$$
-Arg-A(1-21) (I)

in a bacterium;

FINNEGAN HENDERSON FARABOW GARRETT & DUNNERLL

Application No.: 08/402,394

Attorney Docket No. 02481.0790-02

(b) cleaving the expressed compound of step (a) with trypsin resulting in the compound of the formula II

wherein A(1-21) and B(1-30) denote the A and B chains of human insulin and the -S-S-bridges are positioned as in insulin; and

- (c) cleaving the resulting compound of step (b) with carboxypeptidase B.
- 41. (Previously Presented) The method of claim 40, wherein steps (b) and (c) are carried out in one vessel without having to isolate the intermediate compound of the formula II.
- 42. (Currently Amended) A method for the preparation of a mono-Arg-insulin compound of the formula II

FINNEGAN HENDERSON FARABOW GARRETT & DUNNER LLP

Application No.: 08/402,394

Attorney Docket No. 02481.0790-02

in which A(1-21) and B(1-30) denote the A and B chains of human insulin and the -S-S-bridges are positioned as in insulin, which comprises:

(a) expressing a DNA sequence encoding a mini-proinsulin compound of the formula:

in a yeast; and

(b) cleaving said mini-proinsulin compound with trypsin.

FINNEGAN HENDERSON FARABOW GARRETT & DUNNER LLP